A Multicenter Phase I/Ib open label dose escalation study of ABBV-399, and antibody drug conjugate, in subjects with advanced solid tumors.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
March 1, 2014
End Date
February 27, 2023
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
March 1, 2014
End Date
February 27, 2023